Identification of a cancer-associated fibroblast signature for predicting prognosis and immunotherapeutic responses in bladder urothelial carcinoma

References

• Bin Riaz I, Khan AM, Catto JW, et al. Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. Expert Opin Investig Drugs. 2021;30(8):837–855. doi: 10.1080/13543784.2021.1948999.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–436. doi: 10.3322/caac.21731.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708.
   PubMed Web of Science ®Google Scholar
• Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24(10):730–734. doi: 10.1111/iju.13376.
   PubMed Web of Science ®Google Scholar
• Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review. JAMA. 2020;324(19):1980–1991. doi: 10.1001/jama.2020.17598.
   PubMed Web of Science ®Google Scholar
• Fattahi MJ, Haghshenas MR, Ghaderi A. Immunometabolism in the bladder cancer microenvironment. Endocr Metab Immune Disord Drug Targets. 2022;22(12):1201–1216. doi: 10.2174/1871530322666220104103905.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang J, Ruan W, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest. 2020;130(12):6278–6289. doi: 10.1172/JCI139597.
   PubMed Web of Science ®Google Scholar
• Kuzet SE, Gaggioli C. Fibroblast activation in cancer: when seed fertilizes soil. Cell Tissue Res. 2016;365(3):607–619. doi: 10.1007/s00441-016-2467-x.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhou L, Liu L, et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020;11(1):5077. doi: 10.1038/s41467-020-18916-5.
   PubMed Web of Science ®Google Scholar
• Liu B, Pan S, Liu J, et al. Cancer-associated fibroblasts and the related runt-related transcription factor 2 (RUNX2) promote bladder cancer progression. Gene. 2021;775:145451. doi: 10.1016/j.gene.2021.145451.
   PubMed Web of Science ®Google Scholar
• Calon A, Lonardo E, Berenguer-Llergo A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47(4):320–329. doi: 10.1038/ng.3225.
   PubMed Web of Science ®Google Scholar
• Comito G, Giannoni E, Segura CP, et al. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2014;33(19):2423–2431. doi: 10.1038/onc.2013.191.
   PubMed Web of Science ®Google Scholar
• Frings O, Augsten M, Tobin NP, et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am J Pathol. 2013;182(6):2037–2047. doi: 10.1016/j.ajpath.2013.02.018.
   PubMed Web of Science ®Google Scholar
• Derynck R, Turley SJ, Akhurst RJ. TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18(1):9–34. doi: 10.1038/s41571-020-0403-1.
   PubMed Web of Science ®Google Scholar
• Barrett RL, Puré E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. Elife. 2020;9:e57243. doi: 10.7554/eLife.57243.
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Finke J, Montero AJ. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol. 2014;41(2):174–184. doi: 10.1053/j.seminoncol.2014.02.003.
   PubMed Web of Science ®Google Scholar
• Ford K, Hanley CJ, Mellone M, et al. NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors. Cancer Res. 2020;80(9):1846–1860. doi: 10.1158/0008-5472.CAN-19-3158.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. doi: 10.1186/1471-2105-9-559.
   PubMed Web of Science ®Google Scholar
• Zheng H, Liu H, Li H, et al. Weighted gene Co-expression network analysis identifies a Cancer-Associated fibroblast signature for predicting prognosis and therapeutic responses in gastric cancer. Front Mol Biosci. 2021;8:744677. doi: 10.3389/fmolb.2021.744677.
   PubMed Web of Science ®Google Scholar
• Sjödahl G, Lauss M, Lövgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377–3386. doi: 10.1158/1078-0432.CCR-12-0077-T.
   PubMed Web of Science ®Google Scholar
• Lee JS, Leem SH, Lee SY, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010;28(16):2660–2667. doi: 10.1200/JCO.2009.25.0977.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi: 10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044–3050. doi: 10.1093/annonc/mdx518.
   PubMed Web of Science ®Google Scholar
• Finotello F, Trajanoski Z. Quantifying tumor-infiltrating immune cells from transcriptomics data. Cancer Immunol Immunother. 2018;67(7):1031–1040. doi: 10.1007/s00262-018-2150-z.
   PubMed Web of Science ®Google Scholar
• Racle J, de Jonge K, Baumgaertner P, et al. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017;6:e26476. doi: 10.7554/eLife.26476.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi: 10.1038/ncomms3612.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi: 10.1038/s41591-018-0136-1.
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25–29. doi: 10.1038/75556.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. doi: 10.1093/nar/28.1.27.
   PubMed Web of Science ®Google Scholar
• Simon N, Friedman J, Hastie T, et al. Regularization paths for cox’s proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1–13. doi: 10.18637/jss.v039.i05.
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi: 10.1101/gr.239244.118.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi: 10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44. doi: 10.1016/j.cell.2016.02.065.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi: 10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu S, Wang H, et al. ETV4 mediated Tumor-Associated neutrophil infiltration facilitates lymphangiogenesis and lymphatic metastasis of bladder cancer. Adv Sci (Weinh). 2023;10:e2205613.
   PubMedGoogle Scholar
• Huang M, Dong W, Xie R, et al. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program. Cancer Commun (Lond). 2022;42(5):447–470. doi: 10.1002/cac2.12284.
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor microenvironment. Medicina (Kaunas). 2019;56(1):15. doi: 10.3390/medicina56010015.
   PubMed Web of Science ®Google Scholar
• Ke J, Chen J, Liu X. Analyzing and validating the prognostic value and immune microenvironment of clear cell renal cell carcinoma. Anim Cells Syst (Seoul). 2022;26(2):52–61. doi: 10.1080/19768354.2022.2056635.
   PubMed Web of Science ®Google Scholar
• Moore-Smith LD, Isayeva T, Lee JH, et al. Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment. Sci Rep. 2017;7(1):8678. doi: 10.1038/s41598-017-09062-y.
   PubMedGoogle Scholar
• Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–596. doi: 10.1084/jem.20162024.
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–598. doi: 10.1038/nrc.2016.73.
   PubMed Web of Science ®Google Scholar
• Dozier J, Zheng H, Adusumilli PS. Immunotherapy for malignant pleural mesothelioma: current status and future directions. Transl Lung Cancer Res. 2017;6(3):315–324. doi: 10.21037/tlcr.2017.05.02.
   PubMed Web of Science ®Google Scholar
• Cai X, Wang KC, Meng Z. Mechanoregulation of Yap and TAZ in cellular homeostasis and disease progression. Front Cell Dev Biol. 2021;9:673599. doi: 10.3389/fcell.2021.673599.
   PubMed Web of Science ®Google Scholar
• Yao H, Xu K, Zhou J, et al. A tumor microenvironment destroyer for efficient cancer suppression. ACS Biomater Sci Eng. 2020;6(1):450–462. doi: 10.1021/acsbiomaterials.9b01544.
   PubMed Web of Science ®Google Scholar
• Salomé B, Sfakianos JP, Ranti D, et al. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell. 2022;40(9):1027–1043.e9. doi: 10.1016/j.ccell.2022.08.005.
   PubMed Web of Science ®Google Scholar
• Liu S, Shi J, Wang L, et al. Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. Free Radic Biol Med. 2022;189:42–57. doi: 10.1016/j.freeradbiomed.2022.06.247.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Xu X, Chen M, et al. The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo. Cancer Med. 2021;10(13):4437–4450. doi: 10.1002/cam4.3955.
   PubMed Web of Science ®Google Scholar
• Cao R, Wang G, Qian K, et al. TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARγ-SIRT1 feedback loop in human bladder cancer cells. Cancer Lett. 2018;414:278–293. doi: 10.1016/j.canlet.2017.11.015.
   PubMed Web of Science ®Google Scholar
• Deng H, Deng D, Qi T, et al. An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: results from real-world cohorts. Front Genet. 2022;13:1100317. doi: 10.3389/fgene.2022.1100317.
   PubMedGoogle Scholar
• Wu T, Li S, Yu C, et al. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer. Sci Rep. 2022;12(1):21467. doi: 10.1038/s41598-022-26110-4.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhu F, Zhang P, et al. Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation. Front Genet. 2022;13:1074981. doi: 10.3389/fgene.2022.1074981.
   PubMed Web of Science ®Google Scholar
• Yang L, Li C, Qin Y, et al. A novel prognostic model based on Ferroptosis-Related gene signature for bladder cancer. Front Oncol. 2021;11:686044. doi: 10.3389/fonc.2021.686044.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895. doi: 10.1016/S1470-2045(16)30098-5.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi: 10.1016/S0140-6736(19)32222-6.
   PubMed Web of Science ®Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618–627. doi: 10.1016/j.jtho.2019.12.109.
   PubMed Web of Science ®Google Scholar
• Powles T, O'Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411.
   PubMed Web of Science ®Google Scholar
• Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813–820. doi: 10.1158/1078-0432.CCR-15-1678.
   PubMed Web of Science ®Google Scholar
• Zhang X, Shi M, Chen T, et al. Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy. Mol Ther Nucleic Acids. 2020;22:298–309. doi: 10.1016/j.omtn.2020.08.030.
   PubMedGoogle Scholar
• Feng Y, Xiong X, Wang Y, et al. Genomic analysis reveals the prognostic and immunotherapeutic response characteristics of ferroptosis in lung squamous cell carcinoma. Lung. 2022;200(3):381–392. doi: 10.1007/s00408-022-00537-y.
   PubMed Web of Science ®Google Scholar
• He R, Feng X, Yang K, et al. Construction of a 5-methylcytosine-Related molecular signature to inform the prognosis and immunotherapy of lung squamous cell carcinoma. Expert Rev Mol Diagn. 2022;22(9):905–913. doi: 10.1080/14737159.2022.2131396.
   PubMed Web of Science ®Google Scholar
• Zhu G, Pei L, Li Y, et al. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients. Aging (Albany NY). 2020;12(3):2132–2141. doi: 10.18632/aging.102728.
   PubMedGoogle Scholar
• Lv J, Zhu Y, Ji A, et al. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer. Biosci Rep. 2020;40:BSR20194337.
   Web of Science ®Google Scholar
• Pan YH, Zhang JX, Chen X, et al. Predictive value of the TP53/PIK3CA/ATM mutation classifier for patients with bladder cancer responding to immune checkpoint inhibitor therapy. Front Immunol. 2021;12:643282. doi: 10.3389/fimmu.2021.643282.
   PubMed Web of Science ®Google Scholar
• Yi K, Liu J, Rong Y, et al. Biological functions and prognostic value of Ferroptosis-Related genes in bladder cancer. Front Mol Biosci. 2021;8:631152. doi: 10.3389/fmolb.2021.631152.
   PubMed Web of Science ®Google Scholar
• Conconi D, Jemma A, Giambra M, et al. Analysis of copy number alterations in bladder cancer stem cells revealed a prognostic role of LRP1B. World J Urol. 2022;40(9):2267–2273. doi: 10.1007/s00345-022-04093-1.
   PubMed Web of Science ®Google Scholar
• Xie R, Cheng L, Huang M, et al. NAT10 drives cisplatin chemoresistance by enhancing ac4C-Associated DNA repair in bladder cancer. Cancer Res. 2023;83(10):1666–1683. doi: 10.1158/0008-5472.CAN-22-2233.
   PubMed Web of Science ®Google Scholar
• Turkoglu AR, Demirci H, Coban S, et al. Evaluation of the relationship between compliance with the follow-up and treatment protocol and health literacy in bladder tumor patients. Aging Male. 2019;22(4):266–271. doi: 10.1080/13685538.2018.1447558.
   PubMed Web of Science ®Google Scholar
• Tian G, Li Y, Nie L, et al. Cervical lymph node metastasis of bladder cancer: a case report and review of literature. Aging Male. 2023;26:2205935.
   PubMed Web of Science ®Google Scholar